Vadastuximab talirine
- Generic Name
- Vadastuximab talirine
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1436390-64-5
- Unique Ingredient Identifier
- T13V17U431
- Background
Vadastuximab Talirine has been used in trials studying the treatment of Acute myeloid leukemia, Myelodysplastic Syndrome, Acute Myelogenous Leukemia, and Acute Promyelocytic Leukemia.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS
- Conditions
- Interventions
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT02706899
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients
- Conditions
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT02614560
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.